Novartis recognized among 25 best multinational employers by Great Place to Work(R) Institute
Novartis International AG / Novartis recognized among 25 best multinational employers by Great Place to Work® Institute . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.
Great Place to Work® recognizes Novartis for outstanding workplace culture
Inclusion in list of best employers based on survey of 7,200 companies around the world
Novartis ranked high for the pride associates take in their work, their teams and the organization
Basel, October 22, 2013 - Novartis is pleased to announce that it has been named among the Top 25 World's Best Multinational Workplaces by the Great Place to Work® Institute. The list is the world's largest annual study of workplace excellence, identifying the top 25 best multinationals in terms of workplace culture.
The list measures workplaces through five dimensions: credibility, respect and fairness (attributes of trust), as well as pride and camaraderie. Novartis ranked highly on the pride associates take in their work, their teams and the organization. The company also scored well for its credibility and camaraderie among employees. Overall, Novartis received a high score on the Trust Index®, which measures employee perceptions of their workplace.
"At Novartis we are driven by our mission of caring and curing. We strive to attract and retain talented associates who are passionate about improving patients' lives," said Joseph Jimenez, CEO of Novartis. "Being recognized as one of the world's 25 best workplaces reinforces our strong belief that deeply believing in a higher purpose for the organization builds strong associate engagement, and is critical to building a world-leading culture."
With more than 130,000 employees in 140 countries, Novartis is investing in a high- quality portfolio of leadership and career development programs throughout the world, blending experiential learning, coaching, mentoring and training. Alliances with the world's leading business schools and training companies are providing highly customized and top class development opportunities for our talents. Recent emphasis has been in the fastest growing markets. Since 2006 Novartis has built internal universities in China, Asia, Russia and Africa to strengthen the internal talent pipeline and prepare talents to maximize their potential and contribute successfully to the Novartis purpose.
Novartis also encourages its employees to become more involved in their personal health through Be Healthy, the company's global health and well-being program. Great Place to Work® also recognized the Be Healthy Celebration Week as a "Best People Practice."
Novartis qualified for the Top 25 World's Best Multinational Workplaces as a result of being included in 11 Great Place to Work® lists in Argentina, Brazil, Chile, Colombia, Ecuador, Germany, Greece, Mexico, Portugal, Spain and Venezuela.
To qualify for the World's Best Multinational Workplaces List companies must have been selected for at least five national Great Place to Work® lists, have at least 5,000 employees worldwide and count at least 40 percent of their global workforce outside of the company's home country.
To view the entire World's Best Multinational Workplaces list, please visit: http://www.greatplacetowork.com/
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2012, the Group achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 133,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.
# # #
Novartis Media Relations
|Central media line : +41 61 324 2200|
Novartis Global Media Relations
+41 61 324 7999 (direct)
+41 79 593 4202 (mobile)
Novartis Global Media Relations
+41 61 324 7973 (direct)
+41 79 523 0198 (mobile)
Novartis Investor Relations
|Central phone:||+41 61 324 7944|
|Samir Shah||+41 61 324 7944||North America:|
|Pierre-Michel Bringer||+41 61 324 1065||Stephen Rubino||+1 862 778 8301|
|Thomas Hungerbuehler||+41 61 324 8425||Jill Pozarek||+1 212 830 2445|
|Isabella Zinck||+41 61 324 7188|
|e-mail: email@example.com||e-mail: firstname.lastname@example.org|
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: Novartis International AG via Thomson Reuters ONE
--- End of Message ---
Novartis International AG
P.O. Box Basel Switzerland
WKN: 904278;ISIN: CH0012005267;
- China food scandal spreads, drags in Starbucks, Burger King and McNuggets in Japan |
- U.S. courts deliver conflicting rulings on Obama health care law
- Israel pounds Gaza despite international peace efforts |
- EU readies possible capital, tech sanctions on Russia
- Train carrying MH17 bodies on final journey reaches Ukraine city |